Inviragen and PharmaJet receive NIH grant for dengue vaccine

10/10/2010 | American City Business Journals

The NIH's National Institute of Allergy and Infectious Diseases has awarded a five-year, $15.5 million grant to Inviragen and PharmaJet to develop a needleless vaccine that can offer protection against all four strains of dengue virus. Inviragen's DENVax vaccine can be administered using PharmaJet's injector that uses pressurized liquid in drug delivery.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX